21 May 2009
Pre-transplant cellular alloreactivity is predictive of acute graft rejection and one-year graft function in kidney transplant recipientsK Kościelska-Kasprzak, D Drulis-Fajdasz, D Kamińska, O Mazanowska, M Krajewska, W Bieniecki, P Chudoba, W Polak, D Jańczak, D Patrzałek, M Klinger
Ann Transplant 2009; 14(1): 22-22 :: ID: 880278
In our study we investigated the cellular alloimmunity of kidney allograft recipients using direct interferon (IFN)-g enzyme-linked immunospot assay (ELISPOT). Donor splenocytes PBMC of 53 recipients were obtained alongside kidney recovery. 11 recipients presented positive pre-transplant PRA values. For ELISPOT data analysis we calculated number, size and intensity of the spots, which reï¬‚ected the volume of cytokine secretion at the single cell level. The results were recalculated as the ratios of the values observed for donor stimulated and unstimulated recipient cells and corrected for residual donor activity. Significantly higher pre-transplant donor stimulated activity was observed for the recipients who underwent AR episode within one year after Tx (p<0.05). The mean change in the spot number, size and intensity observed for rejectors vs. nonrejectors were 0.99 vs. 3.33, 1.6 vs. 6.05, and 1.4 vs. 6.31, respectively. The assessed parameters were prognostic of high AR risk - 1.5-fold increase in spot number (AR incidence 9% vs. 52%), 2.0-fold increase in size (AR incidence 11% vs. 44%), and 2.7-fold increase in intensity (AR incidence 9% vs. 52%). The three parameters analyzed were correlated with the one year serum creatinine concentration (p<0.05). From 14 AR positive recipients, 11 could have been predicted with pre-transplant ELISPOT measures, while only 2 based upon PRA values. Our data show that the ELISPOT determined volume of donor induced activity observed for the recipient cells obtained just before Tx is predictive of the risk of graft rejection and one-year term graft function.
Keywords: Kidney Transplantation
Most Viewed Current Articles
26 Jan 2022 : Review articleRecurrence of Hepatocellular Carcinoma After Liver Transplantation: Risk Factors and Predictive Models
Ann Transplant 2022; 27:e934924
29 Dec 2021 : Original articleEfficacy and Safety of Tacrolimus-Based Maintenance Regimens in De Novo Kidney Transplant Recipients: A Sys...
Ann Transplant 2021; 26:e933588
24 Jul 2020 : Review articleKidney Transplantation in the Times of COVID-19 – A Literature Review
Ann Transplant 2020; 25:e925755